Skip to Main content Skip to Navigation
Journal articles

Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients

Abstract : Background: Hepatitis E virus (HEV) may be resistant to immunosuppression reduction and ribavirin treatment in kidney transplant recipients because of mutant strains and severe side effects of ribavirin which conduct to dose reduction. Sofosbuvir efficacy is controversial. Peg-interferon 2 alpha (PEG-IFN) is currently contraindicated due to a high risk of acute humoral and cellular rejection. The present study assessed, for the first time, the effect of PEG-IFN in a kidney transplant recipient infected with HEV. Case presentation: The patient had chronic active HEV that was resistant to immunosuppression reduction and optimal ribavirin treatment. He developed significant liver fibrosis. PEG-IFN was administered for 10 months, and it was well tolerated and did not induce rejection. A sustained virological response was obtained. Conclusions: We conclude that prolonged treatment with PEG-IFN in kidney transplant recipients infected with HEV could be considered as a salvage option.
Complete list of metadata

https://www.hal.inserm.fr/inserm-02968132
Contributor : Myriam Bodescot <>
Submitted on : Thursday, October 15, 2020 - 2:18:57 PM
Last modification on : Wednesday, June 2, 2021 - 4:27:03 PM

File

s12879-020-05212-2.pdf
Publication funded by an institution

Identifiers

Citation

Isabelle Ollivier-Hourmand, Louise Lebedel, Angélique Lecouf, Manon Allaire, T Nguyen, et al.. Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients. BMC Infectious Diseases, BioMed Central, 2020, 20 (1), pp.522. ⟨10.1186/s12879-020-05212-2⟩. ⟨inserm-02968132⟩

Share

Metrics